The research focus of the Telethon Kids Cancer Centre is on developing safe new treatments for the deadliest childhood cancers - brain cancer, sarcoma, leukaemia, adolescent melanoma, and neuroblastoma.
The research of the Telethon Kids Cancer Centre is undertaken by laboratory-based scientists, paediatric oncologists, computational biologists, and many higher degree (mainly PhD) and Honours students. Our research is organised into collaborative programs of laboratory-based and translational research.
Our goal is to discover new therapies - therapies that are more effective and less toxic - to fight the most aggressive cancers in babies and children. Our research focuses on:
Harnessing the power of the body's own immune system to fight cancer cells via immunotherapy.
Determining why apparently similar cancer cells from individual patients respond differently to treatment.
Testing existing drugs and new compounds to improve patient outcomes.
Understanding the biology of individual cancers to identify weaknesses to target with therapies.
Developing new treatments with industry partners to feed our drug development pipeline.
The Telethon Kids Cancer Centre has a game changing approach for fighting childhood cancer
Our research strategy is to use our world-first childhood cancer laboratory models to investigate potential new cancer immunotherapies and personalised medicines.
Immunotherapy is an exciting cancer treatment that works by engaging the body’s own immune response to fight the cancer. It promises to be an effective and safe cancer therapy that does not cause the collateral damage of conventional treatments. Immunotherapy has fulfilled this promise for adults with extraordinary results in some cancers. Sadly, the development of immunotherapy treatments for children falls far behind.
Personalised medicine involves performing detailed genetic analysis of individual children with cancer and using the information gained to treat them with drugs that are precisely targeted to the individual tumour. All children with cancer treated in Perth undergo such genetic testing, allowing us to use the genetics of individual’s tumours to inform both treatment development in the laboratory and clinical trial opportunities on the ward.
Our goal is to develop such promising and safe treatments to defeat childhood cancers and reduce the need for toxic chemotherapies and radiotherapies.
If you are interested in potential research collaborations, please contact us.
The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.
Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.
To investigate incidence and survival of childhood tumours of the central nervous system (CNS) by histological subtype, tumour behaviour and tumour grade. Methods: National, population-based data on all children under 15 years old diagnosed with a CNS tumour between 1983 and 2016 were sourced from the Australian Childhood Cancer Registry. Incidence rate trends were calculated using Joinpoint regression.
Infant MLL-AF4-driven acute lymphoblastic leukemia (ALL) is a devastating disease with dismal prognosis. A lack of understanding of the unique biology of this disease, particularly its prenatal origin, has hindered improvement of survival. We perform multiple RNA sequencing experiments on fetal, neonatal, and adult hematopoietic stem and progenitor cells from human and mouse.